ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0390

Vaccination Against COVID-19: Self-Reported Experiences of Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort

Kimberly Showalter1, Jessica Gordon1, Yin Wu2, Linda Kwakkenbos3, Marie-Eve Carrier4, Richard Henry2, Nora Østbø2, Julia Nordlund2, Angelica Bourgeault2, Mara Canedo Ayala2, Marie-Nicole Discepola2, Andrea Carboni Jiménez2, Christopher Denton5, Luc Mouthon6, Brett Thombs7 and Robert Spiera1, 1Hospital for Special Surgery, New York, NY, 2Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, 3Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, 4Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, 5University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, 6Centre de Référence Maladies Autoimmunes Systémiques Rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, 7Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada

Meeting: ACR Convergence 2021

Keywords: COVID-19, Scleroderma, Systemic, Vaccination

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Session Title: Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: COVID-19 vaccination is recommended for individuals with rheumatic diseases, yet data are limited regarding vaccine safety in this population, particularly among those with rare autoimmune conditions such as systemic sclerosis (SSc; scleroderma). The purpose of this cross-sectional, observational study was to evaluate the self-reported experiences of individuals with SSc who have received at least one dose of a COVID-19 vaccine.

Methods: Participants were adults with physician-verified SSc enrolled in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. SPIN includes 47 international centers and has approximately 1600 active participants. From April 9 to May 15, 2021, participants from the SPIN Cohort were invited by email and popups during regular SPIN Cohort assessments to participate in a COVID-19 vaccine survey, which was conducted in English and French. The survey inquired about whether participants had received the COVID-19 vaccine and their experience with vaccination. Frequencies and means (standard deviation (SD)) are reported. Characteristics are compared between those with and without self-reported adverse reactions using chi-square or t-test. Logistic regression was used to compare likelihood of self-reported adverse reactions by vaccine type.

Results: Among 932 responders, 699 (75%) had received at least one dose of a COVID-19 vaccine, and 358 (51%) had also received a second dose. The majority of participants received the Pfizer vaccine (63%). Demographic data are presented in Table 1. Most responders did not make changes to their SSc medications for the first (94%) or second (92%) vaccine dose. Adverse reactions were self-reported in 270 individuals (39%) after the first vaccine dose and 209 individuals (58%) after the second vaccine dose (Table 2). The three most common symptoms after the first and second vaccine dose were sore arm (30% and 45%, respectively), fatigue (23% and 40%, respectively), and muscle aches (9% and 22%, respectively). No serious allergic reactions were reported. Self-reported flares of SSc symptoms were rare after the first (6%) and second vaccine dose (10%), and most common symptoms were fatigue and muscle weakness (Table 2). Those with (vs. without) self-reported adverse reactions (any) to the COVID-19 vaccine were younger (60 vs. 63, p=0.001), more often female (94% vs. 84%, p< 0.001), and more often had a prior history of COVID-19 (10% vs. 5%, p=0.009) (Table 3). Compared to those who received the Pfizer vaccine, the odds of a self-reported adverse reaction were higher for those who received Moderna (OR 1.77, 95% CI 1.20, 2.60) or AstraZeneca (OR 2.20, 95% CI 1.43, 3.39) vaccines.

Conclusion: The rate and types of self-reported adverse reactions to the COVID-19 vaccine among individuals with SSc were similar to those observed in the general population. Few individuals altered their medication regimen for the vaccine, and self-reported worsening of SSc symptoms was rare.


Disclosures: K. Showalter, None; J. Gordon, Cumberland Pharmaceuticals, 5, EICOS Sciences, 5; Y. Wu, None; L. Kwakkenbos, None; M. Carrier, None; R. Henry, None; N. Østbø, None; J. Nordlund, None; A. Bourgeault, None; M. Canedo Ayala, None; M. Discepola, None; A. Carboni Jiménez, None; C. Denton, Acceleron, 2, 6, Actelion, 2, 6, Arxx Therapeutics, 2, 6, Boehringer Ingelheim, 2, 6, Bristol-Myers Squibb, 2, 6, Corbus, 2, 6, CSL Behring, 2, 6, Galapagos NV, 2, 6, GlaxoSmithKline, 2, 6, Horizon, 2, 6, Inventiva, 2, 6, Roche, 2, 6, Sanofi, 2, 6, Servier, 2; L. Mouthon, None; B. Thombs, None; R. Spiera, GSK, 2, 5, Boehringer Ingelheim Pharmaceuticals, 5, Chemocentryx, 2, 5, Corbus Pharmaceutical, 5, Formation Biologics, 2, 5, InflaRx, 5, Kadmon, 5, Astra Zeneca, 5, Abbvie, 2, CSL Behring, 2, Sanofi, 2, Janssen Pharmaceuticals, 2, Genentech/Roche, 2, 5.

To cite this abstract in AMA style:

Showalter K, Gordon J, Wu Y, Kwakkenbos L, Carrier M, Henry R, Østbø N, Nordlund J, Bourgeault A, Canedo Ayala M, Discepola M, Carboni Jiménez A, Denton C, Mouthon L, Thombs B, Spiera R. Vaccination Against COVID-19: Self-Reported Experiences of Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/vaccination-against-covid-19-self-reported-experiences-of-patients-with-systemic-sclerosis-in-the-scleroderma-patient-centered-intervention-network-spin-cohort/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vaccination-against-covid-19-self-reported-experiences-of-patients-with-systemic-sclerosis-in-the-scleroderma-patient-centered-intervention-network-spin-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences